Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment

Investment Overview - Cabaletta's Miraculous Recovery On Potential Best-In-Class Autoimmune Cell Therapy 2024's Sell-Off Explained - Pace of Progress, Manufacturing & Data Woes John M Lund Photography Inc/DigitalVision via Getty Images Cabaletta states that: 2024 actually began well for Cabaletta, with the company receiving an FDA Fast Track award for CABA-201, and Orphan Drug Status in the treatment of systemic sclerosis ("SSc"). At the end of February, however, the share price began to slide. By early Apr ...